Drug metabolizing transgene products, which activate bioreductive cytotoxins, can be used to target treatment-resistant hypoxic tumors. The prodrug AQ4N is bioreduced in hypoxic cells by cytochrome P450s (CYPs) to the cytotoxin AQ4. Previously we have shown that intra-tumoral injection of CYP3A4 and CYP2B6 transgenes with AQ4N and radiation inhibits tumor growth. Here we examine the ability of other CYPs, in particular CYP1A1, to metabolize AQ4N, and to enhance radiosensitization. Metabolism of AQ4N was assessed using microsomes prepared from baculovirus-infected cells transfected with various CYP isoforms. AQ4N metabolism was most efficient with CYP1A1 (66.7 nmol/min/pmol) and 2B6 (34.4 nmol/min/pmol). Transient transfection of human CYP1A17CYP reductase (CYPRED) was investigated in hypoxic RIF-1 mouse cells in vitro using the alkaline comet assay. There was a significant increase in DNA damage following transient transfection of CYP1A1 compared to non-transfected cells; inclusion of CYPRED provided no additional effect. In vivo, a single intra-tumoral injection of a CYP1A1 construct in combination with AQ4N (100 mg/kg i.p.) and 20 Gy X-rays caused a 16-day delay in tumor regrowth compared to tumors receiving AQ4N plus radiation and empty vector (P ¼ 0.0344). The results show the efficacy of a CYP1A1-mediated GDEPT strategy for bioreduction of AQ4N.
Introduction
Tumor hypoxia is known to limit the success of conventional treatments and promote malignant progression. 1, 2 Many attempts have been made to exploit tumor hypoxia especially through the development of hypoxiaactivated cytotoxins such as tirapazamine (TPZ) and AQ4N [1,4-bis [2-(dimethylamino-N-oxide) ethyl] amino 5, 8-di-hydroxyanthracene-9, 10-dione]. Both drugs have shown efficacy in vivo in combination with radiation and established agents, cisplatin and cyclophosphamide. [3] [4] [5] [6] [7] [8] [9] The combination of TPZ with cisplatin in Phase III clinical trial has been encouraging. 3 Furthermore, AQ4N, has shown increased efficacy with less systemic toxicity than TPZ when combined with other agents in preclinical studies; 10, 11 AQ4N is now in Phase I/II clinical trials. 12, 13 It is proposed that a gene-directed prodrug therapy (GDEPT) could further increase reduction of these drugs through enhanced expression of the appropriate enzyme, providing even greater efficacy. Furthermore, hypoxiaactivated prodrugs provide tumor specificity not seen with the standard prodrugs currently used in GDEPT approaches. This strategy has been used to dramatically enhance the metabolism of TPZ following adenoviral delivery of the TPZ-metabolizing enzyme, cytochrome P450 (CYP) reductase (CYPRED) in combination with 10 Gy irradiation to kill the remaining oxic cells that are resistant to the bioreductive drug.
14 In addition, CYPRED was used to enhance the metabolic potential of CYP2B6 allowing a significant improvement in antitumor effect when tumors were treated with the combination of TPZ and CPA. 15 A number of CYPs are capable of reducing AQ4N. 16, 17 We have used these enzymes to develop a GDEPT approach to enhance metabolism of AQ4N. When the prodrug enters a hypoxic cell a two-step irreversible reduction converts AQ4N to AQM and then AQ4 ( Figure 1 ). Previously we have demonstrated that a relatively simple, non-optimized approach, using a single intra-tumoral injection of CYP3A4 transgene, followed by AQ4N and radiation, was effective for controlling tumor growth in vivo; 33% of tumors were locally controlled for 460 days. 18 We have also combined human CYP2B6 in this approach. In vivo a single intratumoral injection of CYP2B6 significantly enhanced tumor growth delay in combination with AQ4N, when either radiation or CPA were used as the oxic cell killer. 19 The use of CYP2B6 also offers the interesting possibility that CPA metabolism could be enhanced in the betteroxygenated cells.
In this paper we report the assessment of another CYP isoform demonstrating that CYP1A1 is also effective as an AQ4N prodrug metabolizing gene when used in combination with radiation in a GDEPT approach.
Materials and methods
Cell culture RIF-1 murine fibrosarcoma cells were routinely maintained by the protocol of Twentyman et al. 20 Cells were maintained as monolayers at 371C under 5% CO 2 /95% air and passaged every 3-4 days. The culture medium contained RPMI 1640 with L-glutamine (10 mM) (Invitrogen, Paisley, UK), foetal bovine serum (15%) (Globe Pharm, Surrey, UK) and penicillin/streptomycin (1%) (Sigma, Poole, UK).
Metabolism of AQ4N by supersomes
Ready-prepared supersomes were obtained from GenTest (UK); GenTest supersomes are prepared by stably expressing human CYP cDNAs using a baculovirus expression system in insect cells (BTI-TN-5B1-4). Supersomes are the microsomal fraction isolated from insect cells, which are rich, in the expressed CYP enzyme and therefore an excellent source of a specific CYP isoform useful for in vitro metabolism studies. Supersomes of this sort are commonly used to assess CYP-mediated metabolism of drugs. Anoxic incubations were performed in an airtight perspex glovebox at 371C. All reagents were purged of oxygen by bubbling with oxygen-free nitrogen and an anoxic environment was confirmed using an O 2 electrode (Hanna H1 9143 microprocessor dissolved O 2 meter). Each reaction mix consisted of 15 mM NADPH, 25 mM AQ4N and 0.1 M potassium phosphate buffer (pH 7.4). Incubates were pre-warmed for 5 min and the reaction initiated with the addition of the supersomes (7.5 pmol). The reaction was quenched at various timepoints by the addition of an equal volume of ice cold 70% ammonium formate buffer (0.5 M, pH 2.5): 30% acetonitrile (pH 2.0).
Detection and quantification of AQ4N and its metabolites by HPLC Samples were centrifuged at 13 000 r.p.m. for 10 min. The supernatant was collected and the protein pellet resuspended in 50 ml of 80% ammonium formate (0.5 M pH 4.2): 20% acetonitrile. This procedure was repeated twice and supernatants were pooled and analyzed using HPLC, essentially as previously described. 21 
Transgene constructs
The human CYP1A1 cDNA was a kind gift from Dr J Horbach (Research Institute of Toxicology, Utrecht, The Netherlands) which was contained within the pLNCX expression vector.
Transient transfection of RIF-1 tumor cells RIF-1 cells were plated at 2 Â 10 6 per flask (T25; Nunc, UK). After 24 h, the cells were transfected with 12 mg of CYP1A1 construct using Lipofectamine Plus (Invitrogen, Paisley, UK) according to the manufacturer's instructions. The controls included parental non-transfected cells, cells treated with lipofectamine alone and cells transfected with empty vector. After 24 h, the cells were harvested for use in the alkaline comet assay (ACA; see below). In control experiments using the pEGFP reporter gene construct (Clontech, UK), we were able to obtain transfection efficiencies of 25-35% (data not shown).
Determination of AQ4N-induced DNA damage using the ACA At 24 h after transfection, the RIF-1 cells were incubated under hypoxic conditions (95% N 2 /5% CO 2 ) for 30 min prior to addition of 20 mM AQ4N. RIF-1 cells stably expressing 1A1 were treated in the same way. Following 90 min incubation with AQ4N, the drug was removed, cells washed in PBS and DNA damage assessed using the ACA.
Briefly, 1 Â 10 5 cells were immobilized in low melting point agarose on frosted microscope slides (Labcraft, Dakin, UK). Following 1 h lysis at pH 10.0, slides were immersed in electrophoresis buffer for 20 min (to allow the DNA to unwind) and then subjected to alkaline electrophoresis (pH 13.0) for 20 min at 0.83 V/cm (25 V, 300 mA). After washing and neutralization, slides were stained with ethidium bromide. Comets were analyzed and DNA damage quantified using tail moment, defined as the product of the percentage DNA in the tail and the tail length. 18 The mean tail moment was calculated by evaluating 50 cells from each of the three slides for each Bioreductive GDEPT using AQ4N and radiation A Yakkundi et al treatment group. Each experiment was repeated three times. One-way ANOVA was used for statistical analysis.
In vivo transgene delivery in RIF-1 murine tumors and assessment of AQ4N-induced tumor growth delay when used in combination with radiation The RIF-1 syngeneic tumor model was used for in vivo studies. The hypoxic status of the RIF-1 tumor, grown in vivo, has been well characterized, demonstrating a hypoxic fraction of between 1.8 and 4% in established tumors of varying size. 22, 23 The RIF-1 tumor is therefore appropriate for the study of AQ4N, which is activated, in hypoxic conditions, as also demonstrated in our previous studies. . This involved immobilizing the mice in lead jigs with the dorsal tumor exposed to the radiation beam. A single 20 Gy X-ray dose was used since the RIF-1 tumor is a fairly radioresistant tumor model with an SF2 of around 0.7. This dose was found to be synergistic in combination with AQ4N in our previous studies. 18 Control groups consisted of tumors treated with AQ4N, liposomal agent and empty vector. Tumors were measured three times each week and the time for tumors to grow to 4 Â their volume on the day of treatment (tumor volume quadrupling time; VQT) was used as the end point. Growth curves and Kaplan-Meier survival curves were drawn. Statistical comparisons of the Kaplan-Meier survival curves were performed using the Log-Rank test. This function provides a method for comparing two or more survival curves where some of the observations may be censored and where the overall grouping may be stratified. The test is non-parametric in that it does not make assumptions about the distributions of survival estimates. The smallest number of animals was used that still allowed statistically significant differences to be demonstrated in accordance with the Animals (Scientific Procedures) Act 1986 and experiments conformed to the current UKCCCR guidelines.
Detection of human CYP1A1 protein levels by Western blot analysis RIF-1 cells were transfected in vitro with CYP1A1 in the presence of Lipofectamine Plus delivery agent, and harvested 24 h later by isolation in Laemmli buffer (Sigma, UK). The samples were heated to 901C for 10 min. Of each sample, 40 mg was analyzed on 10% BisTris-HCl polyacrylamide gel (Invitrogen, UK). Electrophoresis was carried out at 200 V for 1 h. Protein was transferred onto a nitrocellulose membrane (Hybond C, Amersham, UK) for 1 h at 30 V. The membrane was soaked in Ponceau S stain, rinsed with water and placed in 1% skimmed milk powder (Sigma, UK) for 1 h at room temperature. The primary antibodies (CYP1A1 antibody, Gentest, Cambridge Biosciences, Cambridge, UK; Actin antibody, Sigma, UK) were diluted 1:1000 in 1% blocking solution and added to the membrane overnight at 41C with gentle shaking. The membrane was then washed three times in 25 mM Tris (pH 7.5), 150 mM NaCl and 0.05% Tween 20 and incubated with the secondary antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Inc.) (anti-goat) for 1 h with gentle shaking and the excess removed by the washes described previously. The Pierce Kit (Pierce, UK) was used to assess bound antibody. Blue-sensitive X-ray film was used to detect membrane bound antibody.
Results
In vitro metabolism of AQ4N by CYP supersomes In order to identify which CYPs were most important in the metabolism of AQ4N, we investigated the in vitro metabolism of the drug using the CYP-rich microsomal fraction, prepared from baculovirus-infected cells (BTI-TN-5B1), transfected with various CYPs (Gentest, UK). Equimolar concentrations of CYPs (1A1, 1A2, 1B1, 2B6, 2C8, 2E1) were compared, and AQ4N and its metabolites were quantified by HPLC. There was great variation in the extent of AQ4N metabolism between the various CYP isoforms (Table 1 ). The efficiency of the various CYPs in metabolizing AQ4N can be grouped as high (1A1, 2B6), moderate (1A2) or low (1B1, 2C8 and 2E1). Subsequently we concentrated on a more extensive study of CYP1A1 and CYP2B6. A time course following the in vitro metabolism of AQ4N by CYP1A1 or CYP2B6 was conducted under hypoxic conditions (Figure 2a and  b) . Both isoforms completely metabolized AQ4N by 60 min, however, CYP1A1 was more efficient at metabolizing AQ4N than CYP2B6, with an initial rate of loss of AQ4N of 66.7 nmol/min/pmol compared with 34.4 nmol/min/pmol for CYP2B6 (Figure 2c ).
Determination of AQ4N-induced DNA damage in RIF-1 cells
Since we had demonstrated that CYP1A1 supersomes isolated from baculovirus-infected insect cells were efficient at metabolising AQ4N, we then wanted to test whether CYP1A1-mediated metabolism could increase cytotoxicity in a more relevant tumor cell line in vitro. DNA damage was therefore measured using the ACA following transient transfection of a CYP1A1 cDNA construct and exposure to AQ4N. The ACA is a useful marker of AQ4N metabolism since its metabolite, AQ4, intercalates into DNA resulting in damage that can be measured effectively using the comet assay, while the prodrug, AQ4N, does not bind DNA and causes no DNA damage. The assay was carried out in anoxic conditions that are required for the metabolism of AQ4N. Transfection efficiencies routinely achieved in this cell line using a pEGFP reporter gene were 25-35% (data not shown). CYPRED was co-transfected along with CYP1A1, in one group, as it has been described as a rate-limiting component of P450-dependent drug activation. 24, 25 Background levels of DNA damage (o4 mean tail moment) were detected in the control groups (i.e. parental cells7AQ4N, Lipofectamine Plus with AQ4N, empty vector þ AQ4N and CYPRED þ AQ4N). These data demonstrate that in vitro the RIF-1 tumor cell line does not express endogenous CYPs capable of metabolizing AQ4N under hypoxic conditions. Cells transiently transfected with either CYP1A1 alone or CYP1A1/CYPRED showed mean tail moments of 10.5 and 8.8, respectively (Figure 3) . Furthermore, compared to the vector control, transient transfection of CYP1A1 or CYP1A1/CYPRED significantly increased the severity of DNA damage (P ¼ 0.001).
Detection of CYP1A1 expression by Western blot analysis
Western blot analysis was used to measure the levels of the CYP1A1 protein in transiently transfected RIF-1 tumor cells. RIF-1 cells in culture were transiently transfected with CYP1A1 cDNA under the control of the constitutive CMV promoter within the pLNCX plasmid vector using the Lipofectamine Plus delivery agent. Transfected cells showed a considerable induction of CYP1A1 expression compared to non-transfected cells, Transiently transfected cells were preincubated in hypoxia (95% N 2 /5% CO 2 ) for 30 min, followed by exposure to AQ4N (20 mM), for 90 min under hypoxia. The cells were washed twice with PBS and fresh medium added. The DNA damage was measured 24 h later using the ACA and expressed as the mean tail moment. ***P-values for these two treatment groups are o0.001 when compared to the empty vector control.
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CYP1A1-enhanced tumor growth delay in combination with AQ4N and radiation
We have demonstrated that CYP1A1 is effective at metabolizing AQ4N and can also mediate a cytotoxic effect in transiently transfected, hypoxic RIF-1 tumor cells in vitro. In order to test whether this would have clinical efficacy, this GDEPT approach was subsequently examined in vivo using the same tumor model. Since AQ4N could only target hypoxic tumor cells, this approach was used in combination with radiation, as an oxic cell killer, as this approach was successful in our previous studies. 7, 18, 19 Tumor growth curves demonstrated that a single injection of the CYP1A1 transgene followed by exposure to AQ4N (100 mg/kg) and radiation (20 Gy) delayed tumor growth compared to the empty vector controls (Figure 5b ). Kaplan-Meier survival curves (Figure 5a ) and the mean VQT (Table 2) show that the tumors of untreated mice reached their VQT by 8.8 days. Tumors treated with radiation alone showed 16 days growth delay compared to the untreated control. As expected AQ4N alone did not have any significant effect on tumor growth as it targets only hypoxic cells. Tumors injected with liposomal delivery agent or empty vector and exposed to AQ4N plus radiation reached their mean VQT by 32 days resulting in a further The transgene was injected intratumorally using the Mirus liposome -delivery agent, and 24 h later treated with AQ4N (100 mg/kg) and a further 30 min later with 20 Gy X-rays. Tumor volumes were measured three times a week and mice were killed at the volume quadrupling time (VQT). P ¼ 0.0344 when the CYP1A1 transgene group is compared with the group treated with the empty vector instead; Log-Rank test. *Tumor volume for one mouse did not reach the quadrupling volume and the mouse had to be killed due to disseminated disease. The tumor volume for one mouse in this group did not reach its VQT, but the mouse had to be killed due to disseminated disease.
7 days growth delay when compared to radiation alone. This was similar to that achieved for those tumors receiving AQ4N and radiation without empty vector.
Mice receiving a single intra-tumoral injection of the CYP1A1 construct and exposed to AQ4N and radiation reached their VQT by 47.4 days, resulting in a significant anti-tumor effect (P ¼ 0.0344; Log-Rank test); this represents an additional 16 days growth delay compared to those tumors receiving AQ4N, radiation and empty vector.
Discussion
We have already demonstrated that the anti-tumor efficacy of AQ4N can be increased by delivery of genes encoding the appropriate drug metabolizing enzymes to syngeneic mouse tumors in a GDEPT strategy. Intratumoral injection of a CYP3A4 construct into established RIF-1 murine tumors increased the efficacy of AQ4N, and when used in combination with radiation, three out of nine tumors were locally controlled for 460 days. This was the first demonstration that CYPs could be used in a GDEPT strategy for bioreduction of the cytotoxic prodrug, AQ4N. More recently, we have demonstrated that the CYP2B6 isoform, although less efficient, was also capable of increasing AQ4N anti-tumor efficacy in a GDEPT approach, combined with radiation or cyclophosphamide. 19 Clearly, these data demonstrate that tumors may not contain the appropriate CYP complement for maximal drug activation, consequently enhancement of enzyme levels through a GDEPT strategy may offer an additional approach to target radiation-and chemoresistant hypoxic tumors that should increase overall tumor control.
Several studies have demonstrated indirectly the importance of CYPs in the bioreductive activation and cytotoxicity of AQ4N. 16, 17, 26 Initially we evaluated a range of CYPs in vitro, to assess which is most efficient in the bioreduction of AQ4N to its toxic species AQ4. Microsomal preparations from baculovirus-infected cells (BTI-TN-5B1) transfected with various CYPs were evaluated for their ability to reduce AQ4N; CYP1A1 was superior to all other isoforms studied, closely followed by CYP2B6. Raleigh et al., 16 found no correlation between CYP1A protein expression and AQ4N metabolism. However, no information was given as to whether the polyclonal antibody used was raised against CYP1A1 or 1A2 isoforms. In addition, since CYP1A1 is primarily located in extra-hepatic tissues, such as lung, lymphocytes and placenta, [27] [28] [29] [30] [31] [32] it is unlikely to have been present in the liver microsomal fractions used by Raleigh et al. This is the first report suggesting that CYP1A1 can metabolise AQ4N and since CYP1A1 expression is high in various types of ovarian cancers compared with benign epithelia, 33 our data suggest that targeting these tumor types in combination with oxic cell killers, such as radiation or chemotherapy, even in the absence of a GDEPT approach, may be beneficial.
Since CYP1A1 appeared to be most effective in the reductive metabolism of AQ4N, expression of this isoform was further evaluated in vitro in order to test AQ4-induced cytotoxicity in a relevant tumor model. AQ4-induced DNA damage was evident in hypoxic RIF-1 tumor cells transiently transfected with CYP1A1. The level of DNA damage, as measured by mean tail moment, was comparable to that obtained for CYP3A4 and CYP2B6. 18, 19 Again, as reported in our previous studies, co-transfection of CYPRED did not affect the level of DNA damage.
In vivo evaluation of CYP1A1 in a GDEPT strategy using the RIF1 tumor model shows promising results. In this tumor model, AQ4N, as a single agent or in combination with the oxic cell killer, radiation, does not have a statistically significant antitumor effect, consistent with our previously published observations. 18, 19 In this study a simple, non-optimized, single injection of the CYP1A1 construct using a commercially available liposomal delivery agent, resulted in a significant inhibition of tumor cell growth when combined with AQ4N and radiation. Although this resulted in a statistically significant (Po0.0344) growth delay of 16 days when compared to AQ4N, radiation and empty vector alone, this GDEPT combination was not as effective as CYP3A4 where three of nine tumors were locally controlled for 460days. The CYP1A1 data more closely resemble those obtained for CYP2B6, 19 which is consistent with the in vitro supersome metabolism studies.
In summary, we have demonstrated for the first time that CYP1A1 can effectively metabolize AQ4N. This was not detected in previous studies using human liver microsomes, now known to be low in CYP1A1. Since there is considerable variability in CYP isoform expression between tumor types and even between individual patients, these data suggest a wider clinical applicability for AQ4N even without the addition of a GDEPT strategy. Nevertheless, we have demonstrated that CYP1A1 GDEPT is an effective strategy for the enhancement of the reductive activation of AQ4N and the data compliment our previous reports that demonstrate significant GDEPT activity with CYP2B6 and 3A4.
Furthermore, since we have now successfully identified three CYP isoforms capable of increasing the metabolism of AQ4N in a GDEPT strategy, this will allow more flexibility for its incorporation into conventional treatments. For example, GDEPT combining cyclophosphamide with AQ4N would be best suited to CYP2B6 GDEPT, since it is important for the activation of both drugs. 34 Whereas, CYP1A1 or 3A4 would be better in combination with radiation. Conversely, a GDEPT strategy of CYP3A4 in combination with AQ4N and taxol would not be appropriate as CYP3A4 is known to metabolize and inactivate taxol. 35 
